Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology?

Gartrell, Benjamin A

Clinical decision making in castration-resistant prostate cancer according to baseline prostate-specific antigen: are we measuring disease burden or disease biology? [electronic resource] - European urology Feb 2015 - 231-2 p. digital

Publication Type: Editorial; Comment

1873-7560

10.1016/j.eururo.2014.08.069 doi


Antineoplastic Agents--therapeutic use
Humans
Kallikreins--blood
Male
Phenylthiohydantoin--analogs & derivatives
Prostate-Specific Antigen--blood
Prostatic Neoplasms, Castration-Resistant--drug therapy